Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2026 | Common comorbidities in Tourette syndrome and challenges with current treatments

Kinga Tomczak, MD, PhD, Boston Children’s Hospital, Boston, MA, discusses common comorbidities in Tourette syndrome, including ADHD, anxiety, and OCD, and challenges with current treatments. She emphasizes concerns around weight gain, metabolic effects, and cognitive issues, highlighting the need for therapies that control tics while minimizing broader impacts on patients. This interview took place at the 78th American Academy of Neurology (AAN) Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

As I mentioned already before, in terms of the comorbidities, that’s something that this population, over 90%, 96, some studies show, percent of patients with Tourette syndrome have comorbid neuropsychiatric conditions. The most common is ADHD, oftentimes anxiety, OCD, also in some cases depression, could be learning disabilities and other things. So with the current medications, these antidopaminergic or antipsychotic D2R modulators, we have noticed that they can unfortunately cause changes in hemoglobin A1C or other markers of these so-called metabolic side effects, as well as the weight gain is the primary challenge, especially keeping in mind that nowadays even children often tend to be overweight so it’s a real problem if they have not had a good response to the first line medications and they continue to have pretty significant tics and we were worried to give them a medication that will give them potential further weight gain...

As I mentioned already before, in terms of the comorbidities, that’s something that this population, over 90%, 96, some studies show, percent of patients with Tourette syndrome have comorbid neuropsychiatric conditions. The most common is ADHD, oftentimes anxiety, OCD, also in some cases depression, could be learning disabilities and other things. So with the current medications, these antidopaminergic or antipsychotic D2R modulators, we have noticed that they can unfortunately cause changes in hemoglobin A1C or other markers of these so-called metabolic side effects, as well as the weight gain is the primary challenge, especially keeping in mind that nowadays even children often tend to be overweight so it’s a real problem if they have not had a good response to the first line medications and they continue to have pretty significant tics and we were worried to give them a medication that will give them potential further weight gain. So sometimes we have, so far before this drug, we didn’t have a choice and we would try it. And then we had to give them a medication to lose weight, which was unfortunate. There’s another compound or drug currently that is used for tics. Again, it’s off-label. It’s called topiramate, Topamax, and that can cause weight loss, but the problem is these patients may have some cognitive fogging, and so that’s also not a good option.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

Dr Tomczak has been a clinical investigator for Noema Pharma and Emalex Biosciences (money was received by the institution) and has received consulting fees from Jazz Pharma, Emalex Biosciences, Frazier Sciences, AlphaSights, GLG, Guidepoint and Expert Connect.